American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 868-875 , November 2008

The Association of Podocin R229Q Polymorphism With Increased Albuminuria or Reduced Estimated GFR in a Large Population-Based Sample of US Adults

  • Anna Köttgen, MD, MPH

      Affiliations

    • Johns Hopkins University, Baltimore, MD
    • ,
  • Charles C. Hsu, PhD

      Affiliations

    • Johns Hopkins University, Baltimore, MD
    • ,
  • Josef Coresh, MD, PhD

      Affiliations

    • Johns Hopkins University, Baltimore, MD
    • ,
  • Alan R. Shuldiner, MD

      Affiliations

    • University of Maryland, Baltimore, MD
    • ,
  • Yvette Berthier-Schaad, PhD

      Affiliations

    • Johns Hopkins University, Baltimore, MD
    • Laboratory of Genomic Diversity, Science Applications International Corporation-Frederick, National Cancer Institute, Frederick, MD
    • ,
  • Tejal Rami Gambhir, MPH

      Affiliations

    • Johns Hopkins University, Baltimore, MD
    • ,
  • Michael W. Smith, PhD

      Affiliations

    • Laboratory of Genomic Diversity, Science Applications International Corporation-Frederick, National Cancer Institute, Frederick, MD
    • Basic Research Program, Science Applications International Corporation-Frederick, National Cancer Institute, Frederick, MD
    • ,
  • Eric Boerwinkle, PhD

      Affiliations

    • University of Texas, Houston, TX
    • ,
  • W.H. Linda Kao, PhD, MHS

      Affiliations

    • Johns Hopkins University, Baltimore, MD
    • Corresponding Author InformationAddress correspondence to W.H. Linda Kao, PhD, MHS, 615 N Wolfe St, Rm W6513, Baltimore, MD 21205

Received 8 November 2007 ,Accepted 14 February 2008.

References 

  1. Roselli S, Gribouval O, Boute N, et al. Podocin localizes in the kidney to the slit diaphragm area. Am J Pathol. 2002;160:131–139
  2. Boute N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet. 2000;24:349–354
  3. Caridi G, Bertelli R, Carrea A, et al. Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol. 2001;12:2742–2746
  4. Karle SM, Uetz B, Ronner V, Glaeser L, Hildebrandt F, Fuchshuber A. Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2002;13:388–393
  5. Tsukaguchi H, Sudhakar A, Le TC, et al. NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest. 2002;110:1659–1666
  6. Caridi G, Bertelli R, Scolari F, Sanna-Cherchi S, Di Duca M, Ghiggeri GM. Podocin mutations in sporadic focal-segmental glomerulosclerosis occurring in adulthood. Kidney Int. 2003;64:365
  7. Caridi G, Bertelli R, Di Duca M, et al. Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol. 2003;14:1278–1286
  8. Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int. 2004;66:571–579
  9. Dusel JA, Burdon KP, Hicks PJ, Hawkins GA, Bowden DW, Freedman BI. Identification of podocin (NPHS2) gene mutations in African Americans with nondiabetic end-stage renal disease. Kidney Int. 2005;68:256–262
  10. Franceschini N, North KE, Kopp JB, McKenzie L, Winkler C. NPHS2 gene, nephrotic syndrome and focal segmental glomerulosclerosis: A huge review. Genet Med. 2006;8:63–75
  11. Zhang SY, Marlier A, Gribouval O, et al. In vivo expression of podocyte slit diaphragm-associated proteins in nephrotic patients with NPHS2 mutation. Kidney Int. 2004;66:945–954
  12. ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. Am J Epidemiol. 1989;129:687–702
  13. National Heart, Lung and Blood Institute: Atherosclerosis Risk in Communities (ARIC) Study. Operations Manual 7: Blood Collecting and Processing. Bethesda, MD: National Heart, Lung and Blood Institute; 1988;
  14. National Heart, Lung and Blood Institute: Atherosclerosis Risk in Communities (ARIC) Study. Operations Manual 8: Lipid and Lipoprotein Determinations. Bethesda, MD: National Heart, Lung and Blood Institute; 1987;
  15. National Heart, Lung and Blood Institute: Atherosclerosis Risk in Communities (ARIC) Study. Operations Manual 10: Clinical Chemistry Determinations. Bethesda, MD: National Heart, Lung and Blood Institute; 1987;
  16. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–2100
  17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130:461–470
  18. Coresh J, Astor BC, McQuillan G, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis. 2002;39:920–929
  19. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47–55
  20. Pereira AC, Pereira AB, Mota GF, et al. NPHS2 R229Q functional variant is associated with microalbuminuria in the general population. Kidney Int. 2004;65:1026–1030
  21. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–S266
  22. Thorisson GA, Smith AV, Krishnan L, Stein LD. The international HapMap project web site. Genome Res. 2005;15:1592–1593
  23. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res. 2001;29:308–311
  24. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med. 2002;4:45–61
  25. Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007;39:977–983
  26. Kotowski IK, Pertsemlidis A, Luke A, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet. 2006;78:410–422
  27. Caridi G, Perfumo F, Ghiggeri GM. NPHS2 (podocin) mutations in nephrotic syndrome. Clinical spectrum and fine mechanisms. Pediatr Res. 2005;57:54R–61R
  28. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007;445:881–885
  29. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–678
  30. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med. 2006;354:1387–1401

 Originally published online as doi:10.1053/j.ajkd.2008.02.306 on May 16, 2008.

PII: S0272-6386(08)00536-2

doi: 10.1053/j.ajkd.2008.02.306

American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 868-875 , November 2008

Article Tools

* Image Usage & Resolution